SCHEMBL13128984

SCHEMBL13128984

Cc1ccccc1NS(=O)(=O)c1cc([N+](=O)[O-])ccc1N/N=C/c1ccc(O)c(O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 6/20 0.55
▸ ALPL P05186 2/20 0.55
▸ PSMD14 O00487 1/20 0.55
▸ ALPI P09923 1/20 0.55
▸ ALPG P10696 1/20 0.55
▸ NSD2 O96028 2/20 0.53
▸ MAPT P10636 13/20 0.52
▸ TNNI3 P19429 1/20 0.52
▸ TNNT2 P45379 1/20 0.52
▸ TNNC1 P63316 1/20 0.52
▸ MEN1 O00255 11/20 0.50
▸ KMT2A Q03164 11/20 0.50
▸ ALDH1A1 P00352 6/20 0.50
▸ GAA P10253 5/20 0.50
▸ GLA P06280 1/20 0.50
▸ TLR9 Q9NR96 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.48
▸ POLB P06746 2/20 0.48
▸ PKM P14618 1/20 0.48
▸ GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2741007 0.89 MEN1 (0.58) L3MBTL1ALPLPSMD14ALPIALPG
SCHEMBL2740990 0.79 L3MBTL1 (0.57) L3MBTL1ALPLPSMD14ALPIALPG
SCHEMBL2740976 0.76 PSMD14 (0.53) L3MBTL1ALPLPSMD14ALPIALPG
SCHEMBL2740972 0.76 MAPT (0.58) L3MBTL1ALPLPSMD14ALPIALPG
SCHEMBL2740948 0.76 L3MBTL1 (0.55) L3MBTL1ALPLPSMD14ALPIALPG
SCHEMBL28689490 0.75 KMT2A (0.73) L3MBTL1ALPLNSD2MAPTMEN1
SCHEMBL2741006 0.75 MEN1 (0.55) L3MBTL1ALPLPSMD14ALPIALPG
SCHEMBL2740994 0.75 L3MBTL1 (0.59) L3MBTL1ALPLPSMD14ALPIALPG
SCHEMBL3470566 0.75 SMN1; SMN2 (0.67) L3MBTL1MAPTMEN1KMT2AALDH1A1
SCHEMBL2740986 0.74 MEN1 (0.56) L3MBTL1ALPLPSMD14ALPIALPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 L3MBTL1 1642/4885ALPL 4354/4885PSMD14 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback